BIA
VRTX icon

Biondo Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Biondo Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Buy
25,315
+175
+0.7% +$81.6K 1.45% 29
2025
Q4 		$11.4M Buy
25,140
+65
+0.3% +$28K 1.38% 27
2025
Q3 		$9.82M Buy
25,075
+146
+0.6% +$61K 1.23% 32
2025
Q2 		$11.1M Sell
24,929
-220
-0.9% -$101K 1.46% 24
2025
Q1 		$12.2M Sell
25,149
-131
-0.5% -$61K 1.73% 21
2024
Q4 		$10.2M Buy
25,280
+185
+0.7% +$85.8K 1.4% 26
2024
Q3 		$11.7M Buy
25,095
+665
+3% +$319K 1.6% 23
2024
Q2 		$11.5M Buy
24,430
+23,765
+3,574% +$10.3M 1.7% 17
2024
Q1 		$278K Hold
665
– – 0.04% 83
2023
Q4 		$271K Hold
665
– – 0.05% 71
2023
Q3 		$231K Sell
665
-100
-13% -$35K 0.04% 77
2023
Q2 		$269K Hold
765
– – 0.05% 73
2023
Q1 		$241K Buy
+765
New +$229K 0.05% 73
2021
Q2 		– Sell
-32,026
Closed -$6.88M – 88
2021
Q1 		$6.88M Sell
32,026
-37,342
-54% -$8.2M 1.37% 23
2020
Q4 		$16.4M Buy
69,368
+5,430
+8% +$1.25M 3.14% 8
2020
Q3 		$17.4M Sell
63,938
-915
-1% -$252K 3.77% 7
2020
Q2 		$18.8M Sell
64,853
-265
-0.4% -$71.8K 4.75% 5
2020
Q1 		$15.5M Sell
65,118
-1,552
-2% -$356K 5.13% 4
2019
Q4 		$14.6M Buy
66,670
+15,040
+29% +$3.04M 3.37% 8
2019
Q3 		$8.75M Sell
51,630
-4,220
-8% -$747K 2.24% 13
2019
Q2 		$10.2M Buy
55,850
+900
+2% +$157K 2.43% 10
2019
Q1 		$10.1M Buy
54,950
+8,930
+19% +$1.65M 2.54% 11
2018
Q4 		$7.63M Buy
46,020
+3,715
+9% +$644K 2.3% 12
2018
Q3 		$8.15M Buy
42,305
+7,785
+23% +$1.39M 1.94% 14
2018
Q2 		$5.87M Buy
34,520
+545
+2% +$84.5K 1.48% 20
2018
Q1 		$5.54M Buy
33,975
+4,720
+16% +$771K 1.44% 24
2017
Q4 		$4.38M Buy
29,255
+180
+0.6% +$26.7K 1.11% 30
2017
Q3 		$4.42M Buy
29,075
+26,075
+869% +$3.92M 1.22% 25
2017
Q2 		$387K Buy
+3,000
New +$361K 0.11% 69
2016
Q4 		– Sell
-43,612
Closed -$3.8M – 80
2016
Q3 		$3.8M Buy
+43,612
New +$4.12M 1.29% 27

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Biondo Investment Advisors's VRTX Position: Q1 2026 in Review

Biondo Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 0.7% in Q1 2026, buying an estimated $81.6K and bringing the position to 25,315 shares worth $11.3M. The position accounts for 1.45% of the portfolio, ranked #29.

Biondo Investment Advisors first reported a position in VRTX in Q3 2016 and has held it in 30 quarters since. The position peaked at $18.8M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Biondo Investment Advisors held 25,315 shares of Vertex Pharmaceuticals worth $11.3M as of Q1 2026.
  • Biondo Investment Advisors bought 175 Vertex Pharmaceuticals shares in Q1 2026, an estimated $81.6K.
  • Vertex Pharmaceuticals made up 1.45% of Biondo Investment Advisors's portfolio in Q1 2026, its #29 holding.
  • Biondo Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 30 quarters since.
  • Biondo Investment Advisors's Vertex Pharmaceuticals position peaked at $18.8M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Biondo Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.